Phase I/II Multi-Center, Open Label Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors, including Pancreatic Cancer
The purposes of this phase I/II study are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors, including pancreatic cancer, and to identify a recommended phase II dose for evaluation in these patients.
Study ID: CYT-0851-01
Trial Phase: Phase I/II
Trial Sponsor: Cyteir Therapeutics, Inc.
Therapies Used in This Trial: CYT-0851